206 related articles for article (PubMed ID: 35491322)
1. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.
Ogunbona OB; Lin X; Hornick JL; Lubin DJ; Wang Q; Reid MD; Schneider F; Li D; Shin DM; Shi Q
J Am Soc Cytopathol; 2022; 11(4):183-193. PubMed ID: 35491322
[TBL] [Abstract][Full Text] [Related]
2. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
[TBL] [Abstract][Full Text] [Related]
3. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
4. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of Clinicopathologic Features of 9 Cases of
SMARCA4-deficient Non-small Cell Lung Cancer].
Zhao R; Zou Y; Chen H; Chen Y; Liu Y; He M
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):575-582. PubMed ID: 36002194
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
8. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
Mao R; Liu M; Shu X; Li W; Yan W; Li X
Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
[No Abstract] [Full Text] [Related]
9. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report.
Minoshima A; Sugita S; Segawa K; Aoyama T; Ito M; Daimon F; Takenami T; Kido T; Moriya J; Nishikiori H; Hasegawa T
Diagn Cytopathol; 2023 May; 51(5):E149-E154. PubMed ID: 36772934
[TBL] [Abstract][Full Text] [Related]
10. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates.
Mei L; Alikhan M; Mujacic I; Parilla M; Antic T
Acta Cytol; 2019; 63(5):438-444. PubMed ID: 31230044
[TBL] [Abstract][Full Text] [Related]
12. Fine needle aspiration cytology of metastatic SMARCA4-deficient sinonasal teratocarcinosarcoma: First report in literature.
Gopakumar A; Kakkar A; Kaur K; Sikka K; Thakar A; Sharma A; Jain D
Diagn Cytopathol; 2023 Apr; 51(4):E129-E136. PubMed ID: 36680532
[TBL] [Abstract][Full Text] [Related]
13. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
14. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
16. A BAFfling liver aspirate: Metastatic high grade SMARCA4 deficient undifferentiated gastroesophageal junction carcinoma masquerading as a hematolymphoid malignancy.
Kilic AI; Mirza K; Mehrotra S; Pambuccian SE
Diagn Cytopathol; 2019 Jul; 47(7):725-732. PubMed ID: 30897306
[TBL] [Abstract][Full Text] [Related]
17. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology.
Kezlarian B; Montecalvo J; Bodd FM; Chang JC; Riedel E; White C; Rekhtman N; Sauter JL
Cancer Cytopathol; 2023 Aug; 131(8):526-534. PubMed ID: 37278102
[TBL] [Abstract][Full Text] [Related]
19. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y; Decroix E; Blons H; Alifano M; Leroy K; Petitprez F; Boni A; Garinet S; Biton J; Cremer I; Wislez M; Boudou-Rouquette P; Arrondeau J; Goldwasser F; Fournel L; Damotte D; Mansuet-Lupo A
Lung Cancer; 2022 Jul; 169():13-21. PubMed ID: 35597058
[TBL] [Abstract][Full Text] [Related]
20. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
